Arthneeti
All Q3 FY26 results →
B

Biocon Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Biocon Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹416
Market cap₹69.3K Cr
P/E95.3
Updated23 Aug 2026
Read4 min read

The short version

Biosimilars business expected to grow, driven by new product launches; some launched in FY '26 will begin contributing significantly in FY '27. Biosimilars business expected to return to 20%+ growth trajectory next year with mid-20s EBITDA margins, driven by new product launches and market expansion.

From Biocon Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Biosimilars business expected to grow, driven by new product launches; some launched in FY '26 will begin contributing significantly in FY '27.
  • Growth in biosimilars noted to be strong over past several quarters, with a positive outlook on revenue trajectory.
  • Expanded market share and demand in North America, Europe, and emerging markets projected to support growth.
  • Insulin franchise expected to grow, with capacity doubling planned in drug product stage by FY '27.
  • Generics business showing momentum with ongoing launches (e.g., liraglutide) and a solid growth outlook.
  • Continued prioritization of high-margin markets supporting improved profitability alongside volume growth.
  • Supply and demand for insulin remain robust, with plans to expand presence in North America and other markets.

2 more points from Biocon Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Biocon Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Biocon's major capex investments are largely behind them as most facilities, including peptides and drug substance, have been commissioned.
  • The key ongoing investment is doubling insulin drug product capacity, expected to go commercial in fiscal 2027.
  • Drug substance capacity expansion for insulin in Malaysia is expected 1 to 1.5 years after fiscal 2027.
  • Annual group-level capex has moderated from ~$275 million to below $225 million and is expected to reduce further post-Malaysia expansion.
  • Future capex will mainly comprise maintenance expenditures across entities.

2 more points from Biocon Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Biocon Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention the current or expected orderbook or pending orders for Biocon Limited. However, the following related points can be inferred: - Biocon Biologics is experiencing substantial demand for biosimilar products across major markets including the U.S., Europe, and emerging markets. - There is an ongoing ramp-up of production capacity at multiple facilities, including doubling of insulin drug product capacity, indicating preparation for increased order fulfillment. - New biosimilar product launches are expected to contribute to a growth trajectory in revenues over coming quarters.

2 more points from Biocon Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Biocon Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹4.5K Cr, net profit ₹199 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Biocon Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn Ltd (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Biocon Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Biocon Ltd Q3 FY26 results?

Biosimilars business expected to grow, driven by new product launches; some launched in FY '26 will begin contributing significantly in FY '27. Biosimilars business expected to return to 20%+ growth trajectory next year with mid-20s EBITDA margins, driven by new product launches and market expansion.

What is Biocon Ltd share price analysis?

Biocon Ltd currently shows a neutral. The stock trades at a P/E of 95.3 with a market cap of ₹69,295 Cr. Investors should review the full earnings analysis for detailed insights.

Is Biocon Ltd planning capital expenditure?

Biocon's major capex investments are largely behind them as most facilities, including peptides and drug substance, have been commissioned.

Keep Biocon Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.